AO On Site – New York: Uri Aran 'by foot, by car, by bus' at Gavin Brown's Enterprise through February 25, 2012

February 10th, 2012


All photos on site for Art Observed by Elene Damenia.

Uri Aran loves cookies. In his current show, by foot, by car, by bus at Gavin Brown’s Enterprise, the artist explores the eminent childhood snack from a variety of media, discussing them in video, capturing them in photograph, and incorporating them into his large-scale tabletop sculptures, creating a motif of seemingly childish innocence that spans Aran’s vocabulary as a sculptor, illustrator, video, and performance artist.

Already recognized for his “topographic sculptures,” tabletops covered with ready-made objects, drawings, and photographs, alongside cookies, Aran fills in the gaps using projected video and images to create an immersive environment that explores the nature of childhood naivety and nostalgia. The sculptures vacillate between a near compulsion for order and a reckless abandon, occasionally backdropped by scrawled drawings and abstract painting. Stages of life are frequently referenced through photographs littered among the sculptures.

The show also features a number of performance videos from Aran, in which he awkwardly recounts middling details of various name-brand cookies, beseeches his mother to pay attention to something off camera, and describes tennis balls placed below his image.  Other walls bear projected video stills of Sesame Street characters in black and white, often in poses of distress, highlighting Aran’s reoccurring motifs.

- D. Creahan

Related Links:

Exhibition Site [Gavin Brown]
Artist Site [Uri Aran]

Mantle cell lymphoma treatment reviewed.

Blood Weekly March 11, 2004 2004 MAR 11 – (NewsRx.com & NewsRx.net) — The treatment of mantle cell lymphoma has been reviewed.

“During the last few years, new insights into the biology of mantle cell lymphoma have been obtained,” according to hematologists in Germany. “However, with a median survival of only 3 years, mantle cell lymphoma remains the lymphoma subtype with the poorest prognosis.” “At initial diagnosis most patients present with advanced Ann Arbor stage III or IV and conventional chemotherapy hardly alters the continuously declining survival curve,” noted G. Lenz and colleagues at the University of Munich.

“Recently, two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG) clearly confirmed the superiority of a combined immunochemotherapy,” they said. “In a randomized study of the European Mantle Cell Lymphoma Network, consolidation with myeloablative radiochemotherapy followed by autologous stem-cell transplantation improved the progression-free survival in patients younger than 65 years.” “However, relapses are still observed at a high frequency. Thus, new therapeutic strategies such as radioactively labeled antibodies or molecular targeting agents (e.g. Bortezomib or flavopiridol) are urgently warranted to further improve the clinical outcome of mantle cell lymphoma,” the researchers concluded. web site mantle cell lymphoma web site mantle cell lymphoma

Lenz and coauthors published their study in the Annals of Hematology (Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol, 2004;83(2):71-77).

For more information, contact G. Lenz, University of Munich, Grosshadern Hospital, Department of Internal Medicine 3, Marchioninistr. 15, D-81377 Munich, Germany.

Publisher contact information for the journal Annals of Hematology is: Springer-Verlag, 175 Fifth Avenue, New York, NY 10010, USA.

The information in this article comes under the major subject areas of Hematology, Oncology, Pharmaceutical & Drug Development, Stem-Cell Transplantation and Transfusion Medicine.